PureTech Health (LON:PRTC) Stock Price Breaks Below Fifty Day Moving Average – Time to Sell?

PureTech Health plc (LON:PRTC)’s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of GBX 117.99 and traded as low as GBX 107. PureTech Health shares last traded at GBX 111, with a volume of 1,064,621 shares traded.

Analyst Upgrades and Downgrades

Separately, Peel Hunt restated a “buy” rating and issued a GBX 508 target price on shares of PureTech Health in a report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Trading Up 2.8%

The company has a debt-to-equity ratio of 4.78, a current ratio of 4.60 and a quick ratio of 2.51. The company’s 50 day moving average is GBX 117.99 and its two-hundred day moving average is GBX 123.15. The firm has a market cap of £272.15 million, a P/E ratio of -2.34 and a beta of 0.77.

Insider Buying and Selling

In other PureTech Health news, insider Robert Langer bought 93,944 shares of PureTech Health stock in a transaction dated Wednesday, July 29th. The shares were bought at an average price of GBX 1 per share, with a total value of £939.44. Also, insider John LaMattina bought 93,944 shares of PureTech Health stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of GBX 1 per share, for a total transaction of £939.44. Insiders acquired a total of 469,720 shares of company stock valued at $469,720 in the last 90 days. 13.31% of the stock is owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.